Fundraising Fox
EndoVia
1 known investors
Find your way into EndoVia
Sign up to see every warm intro you have to EndoVia
- Paths you didn't know you had: your email and LinkedIn already hold routes to the EndoVia team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EndoVia develops a precision oncology platform that combines experimental biology with computational modeling to match cannabinoid-based cancer treatments to individual patients. It maps cannabinoid and extract libraries against biological targets, uses subtype-specific tumor models and multi-omics profiling, and builds predictive network and digital-twin models to guide therapeutic development.
Founders & leadership
JR
Jan RožancCo-Founder & CEOJan Rožanc has training in systems biology and pharmacology, with expertise in cannabinoids and the endocannabinoid system spanning molecular mechanism studies, signaling networks, and computational approaches. He founded EndoVia Therapeutics to develop a precision oncology platform that uses experimental biology, systems pharmacology, and computational modeling to predict responses to cannabinoid-based cancer treatments and inform patient stratification.
Investors · 1
Frequently asked questions
- What does EndoVia do?
- EndoVia develops a precision oncology platform that combines experimental biology with computational modeling to match cannabinoid-based cancer treatments to individual patients. It maps cannabinoid and extract libraries against biological targets, uses subtype-specific tumor models and multi-omics profiling, and builds predictive network and digital-twin models to guide therapeutic development.
- Who founded EndoVia?
- EndoVia was founded by Jan Rožanc.
- Who are EndoVia's investors?
- EndoVia's investors include Vesna Advisors.